Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

664 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Prognostic factors for survival and factors associated with long-term remission in patients with advanced melanoma receiving cytokine-based treatments: second analysis of a randomised EORTC Melanoma Group trial comparing interferon-alpha2a (IFNalpha) and interleukin 2 (IL-2) with or without cisplatin.
Keilholz U, Martus P, Punt CJ, Kruit W, Mooser G, Schadendorf D, Liénard D, Dummer R, Koller J, Voit C, Eggermont AM. Keilholz U, et al. Among authors: eggermont am. Eur J Cancer. 2002 Jul;38(11):1501-11. doi: 10.1016/s0959-8049(02)00123-5. Eur J Cancer. 2002. PMID: 12110497 Clinical Trial.
Final results of the EORTC 18871/DKG 80-1 randomised phase III trial. rIFN-alpha2b versus rIFN-gamma versus ISCADOR M versus observation after surgery in melanoma patients with either high-risk primary (thickness >3 mm) or regional lymph node metastasis.
Kleeberg UR, Suciu S, Bröcker EB, Ruiter DJ, Chartier C, Liénard D, Marsden J, Schadendorf D, Eggermont AM; EORTC Melanoma Group in cooperation with the German Cancer Society (DKG). Kleeberg UR, et al. Among authors: eggermont am. Eur J Cancer. 2004 Feb;40(3):390-402. doi: 10.1016/j.ejca.2003.07.004. Eur J Cancer. 2004. PMID: 14746858 Clinical Trial.
Chemoimmunotherapy with dacarbazine, cisplatin, interferon-alpha2b and interleukin-2 versus two cycles of dacarbazine followed by chemoimmunotherapy in patients with metastatic melanoma: a randomised phase II study of the European Organization for Research and Treatment of Cancer Melanoma Group.
Punt CJ, Suciu S, Gore MA, Koller J, Kruit WH, Thomas J, Patel P, Lienard D, Eggermont AM, Keilholz U. Punt CJ, et al. Among authors: eggermont am. Eur J Cancer. 2006 Nov;42(17):2991-5. doi: 10.1016/j.ejca.2006.08.012. Epub 2006 Oct 4. Eur J Cancer. 2006. PMID: 17023156 Clinical Trial.
Immunisation of metastatic cancer patients with MAGE-3 protein combined with adjuvant SBAS-2: a clinical report.
Marchand M, Punt CJ, Aamdal S, Escudier B, Kruit WH, Keilholz U, Håkansson L, van Baren N, Humblet Y, Mulders P, Avril MF, Eggermont AM, Scheibenbogen C, Uiters J, Wanders J, Delire M, Boon T, Stoter G. Marchand M, et al. Among authors: eggermont am. Eur J Cancer. 2003 Jan;39(1):70-7. doi: 10.1016/s0959-8049(02)00479-3. Eur J Cancer. 2003. PMID: 12504661 Clinical Trial.
Prognostic value of serial blood S100B determinations in stage IIB-III melanoma patients: a corollary study to EORTC trial 18952.
Bouwhuis MG, Suciu S, Kruit W, Salès F, Stoitchkov K, Patel P, Cocquyt V, Thomas J, Liénard D, Eggermont AM, Ghanem G; European Organisation for Research and Treatment of Cancer Melanoma Group. Bouwhuis MG, et al. Among authors: eggermont am. Eur J Cancer. 2011 Feb;47(3):361-8. doi: 10.1016/j.ejca.2010.10.005. Epub 2010 Nov 17. Eur J Cancer. 2011. PMID: 21087856 Clinical Trial.
Biomarkers in melanoma.
Gogas H, Eggermont AM, Hauschild A, Hersey P, Mohr P, Schadendorf D, Spatz A, Dummer R. Gogas H, et al. Among authors: eggermont am. Ann Oncol. 2009 Aug;20 Suppl 6(Suppl 6):vi8-13. doi: 10.1093/annonc/mdp251. Ann Oncol. 2009. PMID: 19617299 Free PMC article. Review.
The interval between primary melanoma excision and sentinel node biopsy is not associated with survival in sentinel node positive patients - An EORTC Melanoma Group study.
Oude Ophuis CM, Verhoef C, Rutkowski P, Powell BW, van der Hage JA, van Leeuwen PA, Voit CA, Testori A, Robert C, Hoekstra HJ, Grünhagen DJ, Eggermont AM, van Akkooi AC. Oude Ophuis CM, et al. Among authors: eggermont am. Eur J Surg Oncol. 2016 Dec;42(12):1906-1913. doi: 10.1016/j.ejso.2016.05.012. Epub 2016 May 27. Eur J Surg Oncol. 2016. PMID: 27266406
664 results